Author details

Full Name

Keith A A Fox

Affiliation

ORCID

Career Start Year

1979

Papers

709

H Index

128

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37293139	Guideline-directed medical therapies for comorbidities among patients with atrial fibrillation: results from GARFIELD-AF.		2023
37596725	Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registries.	Clin Cardiol	2023
37794616	Towards personalized cardiovascular care: Global Registry of Acute Coronary Events 3.0 score heralds artificial intelligence era.		2023
37704071	Outcomes of Oral Anticoagulation in Atrial Fibrillation Patients With or Without Comorbid Vascular Disease: Insights From the GARFIELD-AF Registry.	Am J Med	2023
36900643	Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF Registry.	Healthcare (Basel)	2023
37191704	Global Variations in Heart Failure Etiology, Management, and Outcomes.	JAMA	2023
37315959	Effectiveness of GRACE risk score in patients admitted to hospital with non-ST elevation acute coronary syndrome (UKGRIS): parallel group cluster randomised controlled trial.		2023
37120728	Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease.	Eur Heart J Cardiovasc Pharmacother	2023
37435777	Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the GARFIELD-AF registry.		2023
37169491	Determinants and clinical outcomes of patients who refused anticoagulation: findings from the global GARFIELD-AF registry.		2023
37042255	Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF.	Circulation	2023
35089380	Use and outcomes of dual antiplatelet therapy for acute coronary syndrome in patients with chronic kidney disease: insights from the Canadian Observational Antiplatelet Study (COAPT).	Heart and Vessels	2022
35577587	Two-year outcomes of UK patients newly diagnosed with atrial fibrillation: findings from the prospective observational cohort study GARFIELD-AF.	British Journal of General Practice	2022
35383832	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.	Eur Heart J Cardiovasc Pharmacother	2022
35751528	Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.	Eur Heart J	2022
35728054	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis.	Circulation	2022
36713019	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis.		2022
33892489	GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.	Eur Heart J Qual Care Clin Outcomes	2022
34191011	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.	Eur Heart J Cardiovasc Pharmacother	2022
34463737	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.	Eur J Prev Cardiol	2022
34985309	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.	Circulation	2022
34508693	Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trial.	Am Heart J	2022
35271932	High-sensitivity cardiac troponin and the diagnosis of myocardial infarction in patients with kidney impairment.	Kidney International	2022
34569249	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial.	J Am Heart Assoc	2021
34021038	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.	Heart	2021
33752439	High-Sensitivity Cardiac Troponin on Presentation to Rule Out Myocardial Infarction: A Stepped-Wedge Cluster Randomized Controlled Trial.	Circulation	2021
33693493	Clinical risk prediction models for the prognosis and management of acute coronary syndromes.	European heart journal. Quality of care & clinical outcomes	2021
33906372	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries.	Circulation	2021
33538248	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial.	J Am Coll Cardiol	2021
34060704	Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry.	Journal of Thrombosis and Haemostasis	2021
33957178	Risk stratification of cardiovascular complications using CHADS-VASc and CHADS scores in chronic atherosclerotic cardiovascular disease.	International Journal of Cardiology	2021
33571477	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF.	Am Heart J	2021
34000088	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial.	Catheterization and Cardiovascular Interventions	2021
34210409	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease.	J Am Coll Cardiol	2021
33606006	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry.	Blood advances	2021
33550362	2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group.	Eur Heart J Acute Cardiovasc Care	2021
34340829	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial.	Atherosclerosis	2021
34337571	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF.	Heart Rhythm O2	2021
32696663	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke.		2021
33295965	Objective Risk Assessment vs Standard Care for Acute Coronary Syndromes: A Randomized Clinical Trial.	JAMA Cardiology	2021
32516805	Performance of the GRACE 2.0 score in patients with type 1 and type 2 myocardial infarction.	European Heart Journal	2021
32997098	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial.	JAMA Cardiology	2021
31358978	The myth of 'stable' coronary artery disease.	Nature Reviews Cardiology	2020
32323192	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.	J Thromb Thrombolysis	2020
32323191	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.	Journal of Thrombosis and Thrombolysis	2020
32323190	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism.	Journal of Thrombosis and Thrombolysis	2020
31850592	Time-trends and treatment gaps in the antithrombotic management of patients with atrial fibrillation after percutaneous coronary intervention: Insights from the CHUM AF-STENT Registry.	Clinical Cardiology	2020
31847794	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry.	International Journal of Stroke	2020
31587565	High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction.	Circulation	2020
31953535	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.	Nat Rev Cardiol	2020